Inflammatory Bowel Disease (IBD) Mouse Models
Boost the development of your novel treatment to improve gut health in individuals with IBD through InnoSerās preclinical expertise and portfolio of IBD mouse models
IBD Mouse Models Key Characteristics
Inflammatory bowel disease (IBD) is a chronic, relapsing inflammation of the intestinal tract with a pathogenesis that is not yet fully understood. IBD encompasses two primary entities: Crohnās disease (CD) and ulcerative colitis (UC). The main pathophysiological features of these diseases can be effectively modeled in mouse models.Ā Ā
Currently, there are multiple, complementary approaches to how IBD can be modeled in rodent models to accurately replicate the human disease pathophysiology.Ā InnoSer offers a range of validated IBD mouse models, including chemically induced, adoptive transfer, and transgenic mouse models. Each model mimics specific aspects of IBD, allowing you to study the efficacy of different therapeutic mechanisms of action, such as reducing inflammation, epithelial repair, microbiome targeting, and innate and/or adaptive immunity modulation. We can facilitate preclinical research focusing on small molecule drugs, anti-inflammatory agents, biologicals, and other innovative treatment modalities. To learn more about InnoSerās available IBD mouse models, download a leaflet below or consult our research expert team. Ā
āĀ Dextran Sulphate Sodium (DSS) mouse model of IBD.
As a preclinical CRO, InnoSer works with well-established and clinically relevant IBD models, complemented with standardized study protocols to ensure consistency and reproducibility of your results. By choosing InnoSer as your preclinical IBD CRO, you will work alongside expert study directors who take a collaborative approach to your study. Ā
With flexible and fast study start times you can perform your IBD research at an accelerated pace. By outsourcing your preclinical IBD studies to InnoSer, you gain access to our in vitro and in vivo immunology drug development portfolio.Ā
Your IBD Research Starts Here.
Access detailed study timelines, essential readouts, and robust validation data for InnoSer’s offered IBD mouse models.Ā
IBD Mouse Models Sample Data
The Dextran Sulfate Sodium (DSS)-Induced Colitis IBD mouse model represents a relatively easy and quick preclinical research model of IBD.
Histological H&E images of colonic mucosa of mice with DSS-induced colitis show inflammation, a decrease in crypt depth, epithelial cell loss, decrease in villus height and villus perimeter.Ā
The Dextran Sulfate Sodium (DSS)-Induced Colitis IBD mouse model represents a relatively easy and quick preclinical research model for IBD.
C57BL/6 male mice were given no treatment, control), or DSS in varying concentrations (1.5%, 2%, 2.5%, and 3%) in drinking water. In response to acute treatment with DSS, mice show a progressive increase in disease activity index (DAI) score, a key marker of IBD disease progression in mice. DAI score takes into account stool composition, bleeding, and percentage of body loss.Ā Ā
The Dextran Sulfate Sodium (DSS)-Induced Colitis IBD mouse model represents a relatively easy and quick preclinical research model for IBD.
C57BL/6 male mice were given no treatment, control), or DSS in varying concentrations (1.5%, 2%, 2.5%, and 3%) in drinking water. In response to acute treatment with DSS, mice show a dose-dependent decrease in colon length. Ā
The Dextran Sulfate Sodium (DSS)-Induced Colitis IBD mouse model represents a relatively easy and quick preclinical research model for IBD.
C57BL/6 male mice were given no treatment, control), or DSS in varying concentrations (1.5%, 2%, 2.5%, and 3%) in drinking water. In response to acute treatment with DSS, mice show a dose-dependent decrease in colon weight (corrected for body weight). Ā
The Dextran Sulfate Sodium (DSS)-Induced Colitis IBD mouse model represents a relatively easy and quick preclinical research model for IBD.
C57BL/6 male mice were given no treatment, control), or DSS in varying concentrations (1.5%, 2%, 2.5%, and 3%) in drinking water. In response to acute treatment with DSS mice show a progressive decline in body weight, confirming the onset of colitis.Ā Ā
IBD Mouse Models Readouts
The People Behind Your Research
CĆ©line Erens, PhD, Immunology Study Director
An expert team led by our immunology study director; CĆ©line Erens works together with you to help you set up optimal study designs. Curating the preclinical testing of your lead compounds with a deep understanding of the field is your solution to accelerating your drug development.
Dr. L.J.A.C (Luuk) Hawinkels, Associate Professor/Head of Research Laboratory Gastroenterology and Hepatology and LUMC, the Netherlands
Dr. Hawinkels acts as an external advisor to InnoSer. His laboratory’s research focuses on IBD, inflammation, and fibroblast cross-talk in the development and progression of gastrointestinal diseases.
Discover Other Related Immunology Mouse Models
Stay Curious: More Articles to Explore
Pancreatic Cancer PDX Models
Last month, November, represented Pancreatic Cancer Awareness Month; a time to focus on the challenges posed by one of the most aggressive and lethal cancer types. Pancreatic cancer accounts for approximately 3% of all diagnosed cancers in Europe, with pancreatic...
Exploring InnoSerās Key In vitro Oncology Services: PD-1 PD-L1 Blockade AssayĀ
Immune Checkpoint Blockade in Oncology Drug DiscoveryĀ In recent years, immune checkpoint blockade has emerged as a groundbreaking therapeutic strategy in immuno-oncology. Programmed cell death 1 receptor (PD-1), and its ligand programmed cell death ligand 1 (PD-L1)...
RENCA Mouse Mouse Model of Renal Cancer
Approximately 400,000 people are diagnosed with kidney cancer annually. Kidney tumors are classified into different subtypes based on the cell of origin. Over 85% of malignant renal cell tumors are RCC, with the other 15% being nephroblastic, mesenchymal and...
Tumor microenvironment (TME) multiplex immunophenotyping analyses
The use of preclinical orthotopic tumors to better recapitulate the tumor microenvironment (TME) Complex interactions between the cellular and structural components of the tumor microenvironment (TME) composed of tumor cells, fibroblasts, endothelial cells, immune...
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com